Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glycogen synthase kinase 3 beta constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling, and regulation of transcription factors and microtubules. The Glycogen Synthase Kinase 3 Beta pipeline drugs market research report outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
GSK3B Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the GSK3B pipeline drugs market are the central nervous system, oncology, genetic disorders, musculoskeletal disorders, ear nose throat disorders, ophthalmology, and undisclosed.
GSK3B Pipeline Drugs Market Analysis, by Therapy Areas, 2022 (%)
For more GSK3B pipeline drugs therapy area insights, download a free report sample
GSK3B Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of action in the GSK3B pipeline drugs market is Glycogen Synthase Kinase 3 Beta Inhibitor.
GSK3B Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the GSK3B pipeline drugs market are oral, intravenous, intratympanic, parenteral, and sublingual.
GSK3B Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)
For more GSK3B pipeline drugs routes of administration insights, download a free report sample
GSK3B Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the GSK3B pipeline drugs market are small molecule and synthetic peptide.
GSK3B Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)
For more GSK3B pipeline drugs molecule type insights, download a free report sample
Competitive Landscape
Some of the leading companies in the GSK3B pipeline drugs market are Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC.
GSK3B Pipeline Drugs Market Analysis, by Companies, 2022 (%)
To know more about the GSK3B pipeline drugs companies, download a free report sample
Glycogen Synthase Kinase 3 Beta Pipeline Drugs Market Report Overview
| Key Therapy Areas | Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Ophthalmology, and Undisclosed |
| Key Mechanism of Actions | Glycogen Synthase Kinase 3 Beta Inhibitor |
| Key Routes of Administration | Oral, Intravenous, Intratympanic, Parenteral, and Sublingual |
| Key Molecule Types | Small Molecule and Synthetic Peptide |
| Leading Companies | Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC |
Segments Covered in the Report
GSK3B Pipeline Drugs Market Therapy Areas Outlook
- Central Nervous System
- Oncology
- Genetic Disorders
- Musculoskeletal Disorders
- Ear Nose Throat Disorders
- Ophthalmology
- Undisclosed
GSK3B Pipeline Drugs Market Mechanism of Actions Outlook
- Glycogen Synthase Kinase 3 Beta Inhibitor
GSK3B Pipeline Drugs Market Routes of Administration Outlook
- Oral
- Intravenous
- Intratympanic
- Parenteral
- Sublingual
GSK3B Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
- Synthetic Peptide
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1).
- Reviews of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key therapy areas in the GSK3B pipeline drugs market are the central nervous system, oncology, genetic disorders, musculoskeletal disorders, ear nose throat disorders, ophthalmology, and undisclosed.
The mechanism of action in the GSK3B pipeline drugs market is Glycogen Synthase Kinase 3 Beta Inhibitor.
The key routes of administration in the GSK3B pipeline drugs market are oral, intravenous, intratympanic, parenteral, and sublingual.
The key molecule types in the GSK3B pipeline drugs market are small molecule and synthetic peptide.
The key companies in the GSK3B pipeline drugs market are Actuate Therapeutics Inc, Alzamend Neuro Inc, AMO Pharma Ltd, Angelini Spa, Ankar Pharma SL, Avenzoar Pharmaceuticals Inc, CerebraMed, Collaborative Medicinal Development LLC, Frequency Therapeutics Inc, and IGC Pharma LLC.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.